Ford Richard L, Knight O'Rese J, Klifto Meredith R, Zhang Alice Yang, Wiesen Christopher A, Fleischman David
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Odom Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
J Curr Glaucoma Pract. 2022 Jan-Apr;16(1):4-10. doi: 10.5005/jp-journals-10078-1358.
The purpose of this retrospective pilot study was to examine the short-term effect of simultaneous Ahmed Glaucoma Valve implantation and cyclophotocoagulation on postoperative outcomes in patients with neovascular glaucoma.
Patient charts were selected for inclusion in this study if they carried a diagnosis of neovascular glaucoma and underwent Ahmed glaucoma valve implantation only, Ahmed glaucoma valve implantation with cyclophotocoagulation, or cyclophotocoagulation only. A total of 55 eyes of 54 patients were selected for data collection and analysis. Main outcome measures included 1-, 3-, and 6-month intraocular pressure and occurrence of the hypertensive phase. Other outcomes included visual acuity, surgical complication rate, and a number of 6-month postoperative ophthalmic medications.
A significantly lower intraocular pressure was seen in the group that received Ahmed glaucoma valve implantation + cyclophotocoagulation compared to the Ahmed glaucoma valve-only group at 3 and 6 months ( = 0.03 and <0.001, respectively). The difference in the occurrence of the hypertensive phase between the Ahmed glaucoma valve-only group and the Ahmed glaucoma valve + cyclophotocoagulation group approached but did not reach significance ( = 0.052). A significantly lower intraocular pressure was also seen in the cyclophotocoagulation-only group compared to the Ahmed glaucoma valve-only group at 3 months ( = 0.006).
Simultaneous Ahmed glaucoma valve implantation and cyclophotocoagulation significantly lowered intraocular pressure at 3 and 6 months compared to Ahmed glaucoma valve implantation alone in patients with neovascular glaucoma.
Neovascular glaucoma is difficult to manage medically and surgically. When surgery is performed, intraocular pressure often remains elevated postoperatively despite aggressive medical management. This study examines a novel method to lower intraocular pressure after Ahmed glaucoma valve implantation in patients with neovascular glaucoma.
Ford RL, Knight ORJ, Klifto MR, A Pilot Study Assessing Treatment Outcomes in Neovascular Glaucoma Using Ahmed Glaucoma Valve with and without Cyclophotocoagulation. J Curr Glaucoma Pract 2022;16(1):4-10.
本回顾性试点研究的目的是探讨同时植入艾哈迈德青光眼引流阀和睫状体光凝术对新生血管性青光眼患者术后结局的短期影响。
如果患者病历诊断为新生血管性青光眼,且仅接受了艾哈迈德青光眼引流阀植入术、艾哈迈德青光眼引流阀植入联合睫状体光凝术或仅接受了睫状体光凝术,则将其纳入本研究。共选取54例患者的55只眼进行数据收集和分析。主要观察指标包括1个月、3个月和6个月时的眼压以及高血压期的发生情况。其他结局指标包括视力、手术并发症发生率以及术后6个月时使用的眼科药物数量。
与仅植入艾哈迈德青光眼引流阀的组相比,接受艾哈迈德青光眼引流阀植入+睫状体光凝术的组在3个月和6个月时眼压显著降低(分别为P = 0.03和P<0.001)。仅植入艾哈迈德青光眼引流阀的组与艾哈迈德青光眼引流阀+睫状体光凝术组之间高血压期的发生率差异接近但未达到显著水平(P = 0.052)。与仅植入艾哈迈德青光眼引流阀的组相比,仅接受睫状体光凝术的组在3个月时眼压也显著降低(P = 0.006)。
对于新生血管性青光眼患者,与单独植入艾哈迈德青光眼引流阀相比,同时植入艾哈迈德青光眼引流阀和睫状体光凝术在3个月和6个月时能显著降低眼压。
新生血管性青光眼在药物和手术治疗方面都很困难。进行手术时,尽管积极进行药物治疗,术后眼压通常仍会升高。本研究探讨了一种在新生血管性青光眼患者植入艾哈迈德青光眼引流阀后降低眼压的新方法。
福特RL,奈特ORJ,克利夫托MR,一项使用有或无睫状体光凝术的艾哈迈德青光眼引流阀评估新生血管性青光眼治疗结局的试点研究。《当代青光眼实践杂志》2022;16(1):4 - 10。